We describe the clinical course of a VEXAS syndrome patient with a somatic UBA1 variant who was treated with an oral steroid and anti-IL-6 therapy (tocilizumab) that lead to the resolution of the systemic symptoms. This evidence concerns the gene UBA1 and VEXAS syndrome.